Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells
- PMID: 2173979
- DOI: 10.1007/BF00689274
Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells
Abstract
C-1027, a new macromolecular peptide antitumor antibiotic produced by a Streptomyces strain, was extremely cytotoxic to cultured cancer cells and markedly inhibited the growth of transplantable tumors in mice. As determined by tritium-labeled precursor-incorporation assay, C-1027 strongly inhibited DNA and RNA synthesis in hepatoma BEL-7402 cells without affecting protein synthesis. After incubation with the hepatoma cells for 4 h, IC50 values for [3H]-thymidine and [3H]-uridine incorporation were 0.00012 and 0.00032 microM, respectively. After 30 min incubation, C-1027 showed much stronger inhibition of [3H]-thymidine incorporation than did Adriamycin, mitomycin C or methotrexate, even at a concentration 10,000 times lower. The effect of C-1027 on pBR322 DNA suggested that the drug could cause single- or double-strand scission of DNA. As determined by flow cytometry, C-1027 delayed the progression of hepatoma cells through the S-phase and blocked the cells at G2+M. Cytological study showed that C-1027 caused a drastic reduction of the mitotic index within 1 h and that an overshot of the mitotic index occurred at 48 h. Our results indicate that C-1027 is an interesting compound with highly potent activity on cellular DNA.
Similar articles
-
Mechanism of action of a new macromolecular antitumor antibiotic, C-1027.J Antibiot (Tokyo). 1990 Apr;43(4):417-21. doi: 10.7164/antibiotics.43.417. J Antibiot (Tokyo). 1990. PMID: 2161819
-
A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity.J Antibiot (Tokyo). 1989 Aug;42(8):1294-8. doi: 10.7164/antibiotics.42.1294. J Antibiot (Tokyo). 1989. PMID: 2759910
-
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.Cancer Chemother Pharmacol. 1995;36(2):149-54. doi: 10.1007/BF00689200. Cancer Chemother Pharmacol. 1995. PMID: 7767952
-
[Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma].Yao Xue Xue Bao. 1993;28(4):260-5. Yao Xue Xue Bao. 1993. PMID: 8213168 Chinese.
-
[Characterization of cell death induced by anticancer antibiotic lidamycin in human hepatoma BEL-7402 cells].Yao Xue Xue Bao. 2001 Mar;36(3):174-8. Yao Xue Xue Bao. 2001. PMID: 12580082 Chinese.
Cited by
-
DNA damage by C1027 involves hydrogen atom abstraction and addition to nucleobases.Bioorg Med Chem. 2012 Aug 1;20(15):4744-50. doi: 10.1016/j.bmc.2012.06.004. Epub 2012 Jun 9. Bioorg Med Chem. 2012. PMID: 22748380 Free PMC article.
-
Tissue distribution and excretion of 125I-lidamycin in mice and rats.World J Gastroenterol. 2005 Jun 7;11(21):3281-4. doi: 10.3748/wjg.v11.i21.3281. World J Gastroenterol. 2005. PMID: 15929183 Free PMC article.
-
Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.Invest New Drugs. 2011 Dec;29(6):1188-97. doi: 10.1007/s10637-010-9463-x. Epub 2010 Jul 2. Invest New Drugs. 2011. PMID: 20596749
-
Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.World J Gastroenterol. 2005 Feb 7;11(5):717-20. doi: 10.3748/wjg.v11.i5.717. World J Gastroenterol. 2005. PMID: 15655829 Free PMC article.
-
Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.Cancer Biother Radiopharm. 2012 Aug;27(6):384-91. doi: 10.1089/cbr.2012.1209. Epub 2012 May 31. Cancer Biother Radiopharm. 2012. PMID: 22651685 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials